Johnson & Johnson (NYSE:JNJ - Get Free Report) saw some unusual options trading on Monday. Stock investors bought 45,802 call options on the stock. This represents an increase of 41% compared to the typical volume of 32,506 call options.
Insider Activity
In other news, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Johnson & Johnson
A number of hedge funds and other institutional investors have recently modified their holdings of JNJ. Hibernia Wealth Partners LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth about $27,000. Tower View Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company's stock worth $40,000 after purchasing an additional 165 shares in the last quarter. Keener Financial Planning LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $40,000. WFA Asset Management Corp boosted its holdings in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company's stock valued at $40,000 after acquiring an additional 97 shares during the period. Finally, Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $44,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
JNJ has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, April 15th. Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, February 6th. Royal Bank of Canada dropped their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 17th. Finally, Morgan Stanley dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $175.86.
Get Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
Johnson & Johnson stock traded up $1.21 during mid-day trading on Monday, reaching $149.12. The company's stock had a trading volume of 10,114,691 shares, compared to its average volume of 7,317,319. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a market capitalization of $359.35 billion, a P/E ratio of 9.30, a PEG ratio of 2.44 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm's fifty day moving average price is $155.97 and its two-hundred day moving average price is $155.57.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. Johnson & Johnson's revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.68 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Monday, May 20th. Johnson & Johnson's dividend payout ratio is presently 29.68%.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
